The Blockcluster Model: An Alternate Path To Profitability
As blockbuster pipelines dwindle, some large manufacturers see building portfolios of drugs for narrow, related clusters of indications as significant market opportunities. Companies such as GSK, Genzyme, Novartis and Pfizer are finding success with assets that truly address an unmet need and have the potential to be reimbursed at a premium price. However, in many cases, the development and commercialization of narrow-indication drugs are not easy tasks.
You may also be interested in...
Pfizer developed crizotinib and its companion diagnostic in just four years after identifying an aberrant ALK gene as the target, spanning a corporate restructuring, the Wyeth integration, and the departure of senior staff in the R&D organization and oncology BU. The next year or so will tell whether Xalkori was a flash in the pan, or whether it marks the long awaited turnaround for Pfizer’s oncology business and a model for nimble drug development.
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications.
Sue Nabi’s success at L’Oreal, where she headed the firm’s global L’Oreal Paris and Lancome businesses, her skin-care savvy as founder of the luxury, “clean, green and vegan” Orveda, and her experience as a career champion of diversity were major draws for Coty, where she begins as CEO on 1 September.